國家衛生研究院 NHRI:Item 3990099045/12110

NHRI > Institute of Molecular and Genomic Medicine > Shiu-Feng Kathy Huang > Periodical Articles > Item 3990099045/12110

Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/12110

Title:	Activation of aryl hydrocarbon receptor by kynurenine impairs progression and metastasis of neuroblastoma
Authors:	Wu, PY;Yu, IS;Lin, YC;Chang, YT;Chen, CC;Lin, KH;Tseng, TH;Kargren, M;Tai, YL;Shen, TL;Liu, YL;Wang, BJ;Chang, CH;Chen, WM;Juan, HF;Huang, SF;Chan, YY;Liao, YF;Hsu, WM;Lee, H
Contributors:	Institute of Molecular and Genomic Medicine
Abstract:	Neuroblastoma (NB) is the most common malignant disease of infancy, and amplification of the MYCN oncogene is closely associated with poor prognosis. Recently, expression of MYCN was shown to be inversely correlated with aryl hydrocarbon receptor (AHR) expression in NB, and overexpression of AHR downregulated MYCN expression, promoting cell differentiation. Therefore, we further investigated the potential of AHR to serve as a prognostic indicator or a therapeutic target in NB. First, the clinical significance of AHR in NB was examined. Positive AHR immunostaining strongly correlated with differentiated histology of NB and predicted better survival for patients. The mouse xenograft model showed that overexpression of AHR significantly suppressed NB tumor growth. In addition, activation of AHR by the endogenous ligand kynurenine (Kyn) inhibited cell proliferation and promoted cell differentiation in vitro and in vivo. Kyn treatment also upregulated the expression of KISS1, a tumor metastasis suppressor, and attenuated metastasis in the xenograft model. Lastly, analysis of KISS1 levels in NB patient tumors using the R2: Genomics Analysis and Visualization Platform revealed that KISS1 expression positively correlated with AHR, and high KISS1 expression predicted better survival for patients. In conclusion, our results indicate that AHR is a novel prognostic biomarker for NB, and that overexpression or activation of AHR offers a new therapeutic possibility for NB patients.
Date:	2019-11
Relation:	Cancer Research. 2019 Nov;79(21):5550-5562.
Link to:	http://dx.doi.org/10.1158/0008-5472.Can-18-3272
JIF/Ranking 2023:	http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0008-5472&DestApp=IC2JCR
Cited Times(WOS):	https://www.webofscience.com/wos/woscc/full-record/WOS:000494363200011
Cited Times(Scopus):	https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85074377304
Appears in Collections:	[Shiu-Feng Kathy Huang] Periodical Articles

Files in This Item:

File	Description	Size	Format
PUB31431462.pdf		17944Kb	Adobe PDF	304	View/Open

Loading...